참고문헌
- Abbasi AN, Zahid S, Karsan F, Ali N, Bhurgri Y (2010). Lymphoma cases referred to the radiation oncology service of a tertiary referral university hospital in Karachi, Pakistan: a retrospective study. Asian Pac J Cancer Prev, 11, 107-10.
- Aftab K, Bhurgri Y, Pervez S (2006). Small B cell Non-Hodgkins Lymphoma in Pakistan. J Pak Med Assoc, 56, 22-5.
- Borovecki A, Korac P, Nola M, Ivankovic D, Jaksic B, Dominis M (2008). Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3. Croat Med J, 49, 625-35. https://doi.org/10.3325/cmj.2008.5.625
- Cheson BD (2008). New staging and response criteria for non- Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am, 46, 213-23. https://doi.org/10.1016/j.rcl.2008.03.003
- Cheson BD, Pfistner B, Juweid ME, et al (2007). Revised response criteria for malignant lymphoma. J Clin Oncol, 25, 579-86. https://doi.org/10.1200/JCO.2006.09.2403
- Choi WW, Weisenburger DD, Greiner TC, et al (2009). A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res, 15, 5494-502. https://doi.org/10.1158/1078-0432.CCR-09-0113
- De Jong D, Xie W, Rosenwald A, et al (2009). Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol, 62, 128-38. https://doi.org/10.1136/jcp.2008.057257
- Fu K, Weisenburger DD, Choi WW, et al (2008). Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol, 26, 4587-94. https://doi.org/10.1200/JCO.2007.15.9277
- Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM (2006). Immunohistochemical classification of de Novo, transformed, and relapsed diffuse large B-Cell lymphoma into germinal center B-Cell and nongerminal center B-Cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med, 130, 1819-24.
- Ilic I, Mitrovic Z, Aurer I, et al (2009). Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol, 90, 74-80. https://doi.org/10.1007/s12185-009-0353-y
- Jaffe ES, Harris NL, Stein H, Isaacson PG (2008). Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood, 112, 4384-99. https://doi.org/10.1182/blood-2008-07-077982
- Jamal S, Moghal S, Mamoon N, (2006). The pattern of malignant tumours: tumour registry data analysis, AFIP, Rawalpindi, Pakistan (1992-2001). J Pak Med Assoc, 56, 359-62.
- Karin ES (2006). Epidemiology and etiology of non-Hodgkin lymphoma - a review. Acta Oncologica, 45, 258-271. https://doi.org/10.1080/02841860500531682
- Lossos IS, Morgensztern D (2006). Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol, 24, 995-1007. https://doi.org/10.1200/JCO.2005.02.4786
- Malumbres R, Chen J, Tibshirani R, et al (2008). Paraffinbased 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood, 111, 5509-14. https://doi.org/10.1182/blood-2008-02-136374
- Muris JJ, Meijer CJ, Vos W, et al (2006). Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 208, 714-23. https://doi.org/10.1002/path.1924
- Mushtaq S, Akhtar N, Jamal S, et al (2008). Malignant lymphomas in Pakistan according to the WHO classification of lymphoid neoplasms. Asian Pac J Cancer Prev, 9, 229-32.
- Oh YH, Park CK (2006). Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci, 21, 397-405. https://doi.org/10.3346/jkms.2006.21.3.397
- Rimsza LM, Leblanc ML, Unger JM, et al (2008). Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood, 112, 3425-33. https://doi.org/10.1182/blood-2008-02-137372
- Saad AA, Awed NM, Abdel-Hafeez ZM, et al (2010). Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes. Saudi Med J, 31, 135-41.
- Sehn LH, Berry B, Chhanabhai M, et al (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 1857-61. https://doi.org/10.1182/blood-2006-08-038257
- Seki R, Ohshima K, Fujisaki T, et al (2009). Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci, 100, 1842-7. https://doi.org/10.1111/j.1349-7006.2009.01268.x
- Sjo LD, Poulsen CB, Hansen M, Moller MB, Ralfkiaer E (2007). Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol, 79, 501-7. https://doi.org/10.1111/j.1600-0609.2007.00976.x
- Veelken H, Vik Dannheim S, Schulte Moenting J, et al (2007). Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol, 18, 931-9. https://doi.org/10.1093/annonc/mdm012
- Wagner SD, Amen F, Trivedi PS, et al (2007). Bcl-6 and c-Myc are rarely co-expressed in adult diffuse large B-cell lymphoma. Leuk Lymphoma, 48, 1510-3. https://doi.org/10.1080/10428190701458491
- Winter JN, Weller EA, Horning SJ, et al (2006). Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 107, 4207-13. https://doi.org/10.1182/blood-2005-10-4222
- Xu JZ, Guo Z, Zhang M, Li X, Li YJ, Rao SQ (2006). Peeling off the hidden genetic heterogeneities of cancers based on disease-relevant functional modules. Mol Med, 12, 25-33.
- Zaja F, Tomadini V, Zaccaria A, et al (2006). CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma, 47, 2174-80. https://doi.org/10.1080/10428190600799946
피인용 문헌
- Prognostic Values of Various Clinical Factors and Genetic Subtypes for Diffuse Large B-cell lymphoma Patients: A Retrospective Analysis of 227 Cases vol.14, pp.2, 2013, https://doi.org/10.7314/APJCP.2013.14.2.929
- SLE and Non-Hodgkin’s Lymphoma: A Case Series and Review of the Literature vol.2017, pp.2090-6897, 2017, https://doi.org/10.1155/2017/1658473